Shawn Khavari
Psychiatry · Edmond, OKNPI 1780723916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 558 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 558 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$973
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$867
- Supernus Pharmaceuticals, Inc.$793
- Sunovion Pharmaceuticals Inc.$575
- plus $5K from 26 others
What the payments were for
- Food & beverage$10,62499%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,300 |
| Otsuka America Pharmaceutical, Inc. | 82 | $1,287 |
| Johnson & Johnson | 53 | $973 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $867 |
| Supernus Pharmaceuticals, Inc. | 41 | $793 |
| Sunovion Pharmaceuticals Inc. | 30 | $575 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $484 |
| Corium, LLC | 25 | $429 |
| Bausch Health US, LLC | 21 | $418 |
| Noven Therapeutics, LLC | 21 | $401 |
| Alkermes, Inc. | 16 | $362 |
| Lundbeck LLC | 17 | $356 |
| Axsome Therapeutics, Inc. | 17 | $344 |
| Eisai Inc. | 12 | $245 |
| Tris Pharma Inc | 14 | $242 |
| Teva Pharmaceuticals USA, Inc. | 10 | $225 |
| Adlon Therapeutics L.p. | 12 | $213 |
| Ironshore Pharmaceuticals Inc. | 9 | $187 |
| Vanda Pharmaceuticals Inc. | 8 | $176 |
| E.r. Squibb & Sons, L.L.C. | 5 | $112 |
| Neurocrine Biosciences, Inc. | 5 | $111 |
| Merck | 5 | $92 |
| Collegium Pharmaceutical, Inc. | 4 | $77 |
| Vertical Pharmaceuticals, LLC | 3 | $73 |
| Jazz Pharmaceuticals Inc. | 4 | $68 |
| Neos Therapeutics, LP | 4 | $63 |
| Harmony Biosciences LLC | 2 | $53 |
| Idorsia Pharmaceuticals US Inc | 2 | $52 |
| Almatica Pharma LLC | 2 | $51 |
| Neuronetics, Inc. | 1 | $36 |
| Shire North American Group Inc | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
How this compares
$10,699 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $39,663 |
| VraylarCariprazine Hcl | 17 | $23,258 |
| RexultiBrexpiprazole | 12 | $16,706 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $7,853 |
| Vilazodone Hcl | 39 | $2,706 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 77 | $2,069 |
| Lurasidone Hcl | 14 | $1,776 |
| Bupropion XlBupropion Hcl | 103 | $1,726 |
| Buspirone Hcl | 74 | $1,683 |
| Atomoxetine Hcl | 28 | $1,634 |
| Aripiprazole | 103 | $1,405 |
| Trazodone Hcl | 164 | $1,270 |
| Duloxetine Hcl | 114 | $1,205 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 45 | $1,147 |
| Escitalopram Oxalate | 64 | $1,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $973 | $39,66312 claims |
| AbbVieVraylar | $1,300 | $23,25817 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,287 | $16,70612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $484 | $7,85322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Edmond
- Jennifer MorrisEdmond$26K
- Dennis HeaneyEdmond$12K
- Melanie BarrettEdmond$3K
- Shyvonne GrayEdmond$2K
- Robert MortonAda$1.9M
- Sarah LandTulsa$287K
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Charles LesterMuskogee$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.